CVS cutting down, adjusting pharmacy hours in two-thirds of stores
CVS cutting down, adjusting pharmacy hours in two-thirds of stores
00:37
CVS and Walmart are reducing their pharmacy operating hours across the U.S. to improve employees’ work-life balance as the chains continue to struggle with staffing shortages in the wake of the COVID-19 pandemic.
CVS said it will be “adjusting hours in select stores” come spring, as part of a periodic review of “operating hours to make sure we’re open during peak customer demand.” The move will affect around two-thirds of the company’s approximately 9,000 retail pharmacies beginning in March, a company spokesperson said in a statement to CBS MoneyWatch.
CVS, which is the largest pharmacy chain in the U.S. by revenue, said it’s making the schedule changes in order to “ensure our pharmacy teams are available to serve patients when they’re most needed,” a CVS spokesperson said. “If a pharmacy is closed, a patient can visit any open CVS Pharmacy location for assistance with their immediate prescription needs,” the spokesperson added.
Walmart reduces hours, raises pay
Walmart also said it’s cutting hours at its pharmacy locations nationwide to improve “work-life balance” for its associates.
Walmart pharmacies will be open from 9 a.m. to 7 p.m. Monday through Friday. Previously they were open until 9 p.m. on weekdays.
“Walmart is committed to helping our associates live better. Walmart has a strong and incredible pharmacy team, and we are making this change to not only enhance their work-life balance but also to maintain the best level of service for our customers,” Walmart said in a statement to CBS MoneyWatch.
Walmart said it’s making the schedule change based on feedback from pharmacy staff and customers.
“By positioning our teams in the hours where our customers say they want to visit our pharmacy, we are better able to deliver excellent customer service and support our associates as they continue to serve their communities every day,” Walmart said.
In mid-June, Walmart announced higher wages for more than 36,000 pharmacy technicians, raising their average hourly pay to more than $20.
Prior to the pandemic, pharmacists and pharmacy technicians outnumbered opportunities for employment, according to Michael Hogue, dean of the Loma Linda University School of Pharmacy.
As the COVID-19 vaccines first began to be rolled out in 2021, regional and national pharmacy chains were clamoring for qualified workers to support the massive public health campaign. Job opportunities for pharmacy students soared.
Walgreens hires more pharmacists, raises pay
A spokesperson for the Walgreens pharmacy chain, the second largest in the U.S., also said it has had to adjust pharmacy hours over the past 12-plus months due to staffing challenges.
Walgreens added that it has hired thousands of pharmacists as well as increased pharmacy workers’ pay to address ongoing staffing issues. It said the efforts are working and the issues are subsiding.
“We have seen positive staffing trends for the past several months as we work to return more stores to normal operating hours,” Walgreens said.
Pharmacies aggressively hired pharmacists and pharmacy technicians starting in February 2021, when COVID-19 vaccines were first made available to the general public, to accelerate efforts to inoculate as many people as possible. Pharmacist job postings surged and drugstore chains offered hefty signing bonuses of up to $20,000.
CVS, the largest U.S. drugstore chain by revenue, plans in March to cut or shift hours at about two-thirds of its roughly 9,000 U.S. locations. Walmart plans to reduce pharmacy hours by closing at 7 p.m. instead of 9 p.m. at most of its roughly 4,600 stores by March.
Walgreens Boots Alliance Inc.
previously said it was operating thousands of stores on reduced hours because of staffing shortages. Combined, the three chains operate some 24,000 retail pharmacies across the U.S.
Walmart last year raised pay for pharmacy technicians.
Photo:
Ryan David Brown for The Wall Street Journal
Earlier in the pandemic, CVS and Walgreens struggled to meet demand for Covid shots and vaccines. The chains cut hours and, in some cases, closed pharmacies for entire weekends. Walmart, which sells a wider variety of goods, cut overall store hours, in part, to cope with Covid-related labor shortages and make time to restock empty shelves as demand for basics such as toilet paper surged.
CVS, in a recent notice to field leaders, said most of its reduced hours will be during times when there is low patient demand or when a store has only one pharmacist on site, which the company said is a “top pain point,” for its pharmacists.
CVS said in a statement it periodically reviews pharmacy operating hours as part of the normal course of business to ensure stores are open during high-demand times. “By adjusting hours in select stores this spring, we ensure our pharmacy teams are available to serve patients when they’re most needed,” the company said, adding that customers who encounter a closed pharmacy can seek help at a nearby location.
At Walmart, the shorter hours offer pharmacy workers a better work-life balance and best serve customers in the hours they are most likely to visit the pharmacy, said a company spokeswoman. “This change is a direct result of feedback from our pharmacy associates and listening to our customers,” she said. Some Walmart pharmacies already close before 9 p.m., which will become standard across the country after the change.
An online community message board for Holliston, Mass., a small town about 30 miles outside Boston, was populated with messages last month from locals venting about the unpredictable hours of the CVS in town, said resident Audra Friend, who does digital communications for a nonprofit. Ms. Friend said she struggled for a week in November to refill a prescription for a rescue inhaler at the store because the pharmacy was sporadically closed.
“I would go in, and there was a note on the door saying, ‘Sorry, pharmacy closed,’” said Ms. Friend, who switched her prescriptions to a 24-hour CVS about 5 miles away. She said it would be better to have consistently shorter hours if that meant fewer unexpected closures. “At least that way we’re not just showing up at CVS to find out the pharmacist isn’t there,” she said.
Newsletter Sign-up
Health
Get a weekly briefing on what’s new in health, medicine, personal well-being and the business of healthcare.
A CVS spokeswoman said that in recent weeks the Holliston store has had no unexpected closures.
The drugstore chains have been working to stop an exodus of pharmacy staff by offering such perks as bonuses, higher pay and guaranteed lunch breaks. Pharmacists were already in short supply before the pandemic, and consumer demand for Covid-19 shots and tests put additional strains on pharmacy operations. Walgreens recently said staffing problems persist and remain a drag on revenue.
Retail pharmacies, which benefited from a bump in sales and profits during the pandemic, are now reworking their business models as demand for Covid tests and vaccines decline and generic-drug sales generate smaller profits.
CVS and Walgreens are closing hundreds of U.S. stores and launching new healthcare offerings as they try to transform themselves into providers of a range of medical services, from diagnostic testing to primary care.
This past summer, Walgreens was offering bonuses up to $75,000 to attract pharmacists, while CVS is working to develop a system in which pharmacists could perform more tasks remotely. The median annual pay for pharmacists was nearly $129,000 in 2021, according to Labor Department data, which also projected slower-than-average employment growth in the profession through 2031.
In the past year, the chains have poured hundreds of millions of dollars into recruiting more pharmacists and technicians but staffing up has proven difficult. Pharmacists remain overworked, pharmacy-chain executives have acknowledged, and fewer people are attending pharmacy schools. The number of pharmacy-school applicants has dropped by more than one-third from its peak a decade ago, according to the Pharmacy College Application Service, a centralized pharmacy-school application service.
Meanwhile, many pharmacists who aren’t quitting the field are leaving drugstores to work in hospitals or with other employers.
Walmart raised wages for U.S. pharmacy technicians in the past year, bringing average pay to more than $20 an hour. Walmart said it planned to raise the minimum wage for all U.S. hourly workers in its stores and warehouses to $14 next month, from $12.
CVS and Walgreens last year raised their minimum wages to $15 an hour.
Write to Sharon Terlep at sharon.terlep@wsj.com and Sarah Nassauer at Sarah.Nassauer@wsj.com
has agreed to pay $3.1 billion to settle opioid-crisis lawsuits brought by several U.S. states and municipalities, adding to a landmark settlement with rival pharmacy chains.
The agreement resolves a collection of lawsuits brought by states, cities and Native American tribes. Earlier this month,
CVS Health Corp.
CVS 1.08%
and
Walgreens
WBA 1.75%
Boots Alliance Inc. agreed to pay roughly $5 billion apiece to settle the lawsuits. The companies didn’t admit wrongdoing in their deals.
The Walmart agreement was announced the same morning that the retail giant reported its latest quarterly results. The company said it took $3.3 billion in charges in the last quarter related to opioid settlements.
Walmart reported stronger-than-expected sales in the October-ended quarter and raised sales and profit goals for the year, signs the big discount chain is drawing in shoppers despite high inflation. Walmart shares rose over 8% in midmorning trading.
Newsletter Sign-up
What’s News
Catch up on the headlines, understand the news and make better decisions, free in your inbox every day.
Each state, local government and tribe will need to decide whether to participate in the settlement. Plaintiff’s attorneys that lead negotiations are encouraging them to do so, saying the payments hold the pharmacies accountable for their alleged roles in the opioid abuse.
Walmart said that it strongly disputes allegations made in the lawsuits and that the settlement isn’t an admission of liability. The company said its settlement payments will reach communities faster than other deals. CVS is paying out over 10 years, and Walgreens over 15 years.
Walmart has roughly half as many locations as either CVS or Walgreens, which combined have roughly 19,000 U.S. drugstores. Walmart has faced scrutiny from the federal government related to how it prescribed opioids.
The Justice Department filed a lawsuit in December 2020 over its alleged role in the opioid crisis, claiming Walmart sought to boost profits by understaffing its pharmacies and pressuring employees to fill prescriptions quickly. The settlement with the states doesn’t cover the federal case, which Walmart has sought to have dismissed.
The Justice Department sued Walmart a few months after the company had pre-emptively sued the federal government, saying the Justice Department and Drug Enforcement Administration were attempting to scapegoat the company for their failings. Walmart’s suit was dismissed in February 2021. Walmart appealed the dismissal, but lost that case late last year.
Opioid abuse has claimed more than half a million lives and triggered more than 3,000 lawsuits by governments, hospitals and others against players in the pharmaceutical industry, including manufacturers, distributors and drugstores.
The fact that Walmart will pay out funds almost immediately rather than over a decade or more “is particularly noteworthy considering that Walmart dispensed fewer opioids, and at lower dosages, than the other pharmacy defendants,” said lawyer
Paul Geller,
of Robbins Geller, a who is representing local communities.
Write to Sharon Terlep at sharon.terlep@wsj.com and Sarah Nassauer at Sarah.Nassauer@wsj.com
Woonsocket, RI-based CVS Health plans to sell its long-term care pharmacy business, Cincinnati-based Omnicare, reporting a $2.5 billion loss related to it in the third quarter, the company announced Wednesday.
“We continue to evaluate our portfolio strategically and are making decisions around assets that don’t fit into our portfolio strategically. Omnicare is a good example of that,” President and CEO Karen Lynch said Wednesday morning on the company’s third-quarter earnings call.
“The Company determined that its LTC business was no longer a strategic asset and during the third quarter of 2022 committed to a plan to sell the LTC business,” CVS said in a filing with the Securities and Exchange Commission on Wednesday, made in conjunction with the call.
Omnicare serves senior living communities, skilled nursing facilities and Programs of All-Inclusive Care for the Elderly (PACE).
For accounting purposes, Omnicare “met the criteria for held-for-sale accounting and the net assets were accounted for as assets held for sale,” the company reported Wednesday. “The carrying value of the LTC business was determined to be greater than its fair value and a loss on assets held for sale was recorded during the third quarter of 2022.”
In the third quarter, according to CVS, the company recorded a $2.5 billion pretax loss on assets held for sale to write down the company’s long-term care business in the current year, which partially was offset by the absence of a $431 million goodwill impairment charge on the remaining goodwill of the Omnicare unit recorded in the prior year.
2015 acquisition
CVS acquired Omnicare in 2015 for $10.4 billion plus the assumption of $2.3 billion in Omnicare debt, according to published sources. At the time, then-CEO Larry Merlo said that the purchase gave the retail pharmacy giant “access into a new pharmacy dispensing channel.”
Rumors of a possible Omnicare sale circulated in August 2020, when a CVS spokeswoman told McKnight’s Senior Living that it would be consolidating positions within the long-term care business. Some put the number of positions at stake at more than 700, although CVS did not confirm a specific amount.
“The healthcare industry is evolving as patients and clients change how they interact with service providers and as payer programs evolve,” Shelly Bendit, a senior communications consultant with CVS Health, said at the time. “We regularly evaluate all of our businesses to ensure that we are positioned to best serve our customers while running our operations as efficiently as possible.”
CVS had not publicly expressed an intention to leave the long-term care business at that point, but a few months earlier, in January 2020, Merlo had described the company’s experience with Omnicare as “disappointing.” In remarks during a J.P. Morgan Healthcare Conference session, he also noted that the skilled nursing sector was “challenged” and that people’s desire to convalesce at home was continuing to affect demand for long-term institutional pharmacy services.
“We continue to see the opportunity in the growth of assisted and independent living, and that’s where our focus remains,” he said at the time, according to a transcript.
On an August 2020 earnings call, CVS executives noted that the COVID-19 pandemic had “substantially affected” Omnicare and the company’s long-term care presence overall.
“As you look at the industry challenges, we’ve seen admissions down about 20% and some facilities continuing to not accept new patients but not be shut down per se,” CVS Health Vice President and Chief Financial Officer Eva Boratto said at the time.
Lynch joined CVS as its new CEO in February 2021. Early this year, effective July 1, Ahmed Hassan was appointed president of Omnicare, having joined CVS Health in 2015. At the time, he called Omnicare “a rock-solid company filled with passionate long-term care experts.”
Costing the company money
But long-term care-related legal actions also have cost the company money.
In May 2020, for instance, Omnicare agreed to pay a $15.3 million civil penalty to settle allegations that it violated federal law by allowing opioids and other controlled substances to be dispensed without a valid prescription.
Omnicare denied the allegations but settled the lawsuit “to avoid the expense and uncertainty of potential litigation,” a company spokesman told McKnight’s Senior Living at the time.
Separately and not specific to long-term care, on Wednesday, CVS announced an agreement in principle to pay approximately $5.2 billion over 10 years, beginning in 2023, to settle what Lynch described as “substantially all opioid lawsuits and claims against CVS Health by states, political subdivisions and tribes.”
That outcome, she said, “is in the best interest of all parties and one that will help put a decades-old issue behind us as we continue to focus on delivering a superior health experience for the millions of consumers who rely on us.”
On the Wednesday earnings call, Lynch also noted that CVS had signed an agreement to sell online benefits enrollment/administration system creator bswift (to global investment firm Francisco Partners), a business she also described as “nonstrategic.” CVS had acquired the company as part of Aetna buy in 2018.
“As we divest assets, we will continue to invest in areas aligned with our strategy with a disciplined approach to capital allocation,” she said. The company also recently sold health savings account business Payflex (to Millennium Trust) and part of its Aetna international business, Lynch noted.
Not all sales
But it’s not all divestitures for the company.
In September, CVS announced that it was buying Signify Health, a company focused on “health risk assessments, value-based care and provider enablement,” for $8 billion.
“This acquisition will enhance our connection to consumers in the home and enables providers to better address patient needs as we execute our vision to redefine the healthcare experience. In addition, this combination will strengthen our ability to expand and develop new product offerings in a multi-payer approach,” Lynch said at the time.
Wednesday, she said that the transaction is expected to close in the first half of next year, and she also hinted at future home-related spending.
“We said we wanted to be in the home. We’ll make investments around that,” Lynch said, echoing comments she made in September at the Morgan Stanley Global Healthcare Conference.
$3B+ revenues expected for segment in 2022
Despite the potential sale of Omnicare, CVS’ retail/long-term care segment is expected to see more than $3 billion in revenues in 2022 due to COVID-19, Executive Vice President and Chief Financial Officer Shawn Guertin said.
“It is not prudent to anticipate a similar level of COVID-based revenues going forward,” however, he said, “and we expect that the economics on vaccines and diagnostic testing will change following the expiration of the public health emergency, which we project will happen in the early part of the first quarter of 2023.”
Overall, the retail/long-term care segment, which includes CVS Pharmacy locations serving the general public in addition to Omnicare, “continues to outperform expectations,” Lynch said, with revenues of $2.67 billion in the quarter representing growth of almost 7% versus the prior year, with $1.4 billion in adjusted operating income, according to executives.
“Performance in both the front store and pharmacy was strong,” Lynch said, noting that front store sales were up approximately 4% and that demand for COVID vaccines and over-the-counter tests, as well as cough, cold and flu products, remains high.
The number of prescriptions filled, she said, grew 1.8% year-over-year in the third quarter, or 3.6% if COVID vaccines are excluded.
“This growth helped propel our retail pharmacy business to another quarter of year-over-year market share gains, extending a trend that started in the first quarter of 2020,” Lynch said.
In addition to its retail/long-term care segment, CVS also has a healthcare benefits segment and a pharmacy services segment.
Overall, Lynch characterized the quarter as “outstanding.”
“During the third quarter, we grew revenue by 10% versus the prior year to over $81 billion and grew adjusted operating income by nearly 4% over the prior year to $4.2 billion,” she said. “Adjusted earnings per share in the quarter was $2.09, an increase of over 6% from the prior year.”
Learn more about the company’s third-quarter performance on the CVS corporate website.
CVS and Walgreens Near $10 Billion Deal to Settle Opioid Cases The New York Times
CVS Health reaches settlement in opioid epidemic KENS 5: Your San Antonio News Source
CVS and Walgreens agree to $10 billion in tentative deals on opioid cases. Walmart will also reportedly settle CNN
Walgreens, CVS, Walmart in $12B opioid settlement • VillageMD may grow by buying rival • Silver Cross, UChicago neuroscience deal Crain’s Chicago Business
CVS, Walgreens to Pay More Than $10 Billion to Settle Opioid Lawsuits The Wall Street Journal
CVS has tentatively agreed to pay $5 billion to settle lawsuits brought by states and local governments alleging the retailers mishandled prescriptions of opioid painkillers.
Two other major retailers – Walgreens and Walmart – have tentatively agreed to pay billions of dollars to settle similar lawsuits, according to reports from Bloomberg and Reuters.
The deal calls for Walgreens to pay at least $4 billion and Walmart to pay $3 billion, Bloomberg reported, citing sources familiar with the matter.
The agreement wouldn’t be finalized until enough states, counties and cities agree to the terms, Bloomberg said.
CNN has reached out to the companies for comment.
CVS said if the settlement is reached, it would pay the states over 10 years beginning in 2023.
“We are pleased to resolve these longstanding claims and putting them behind us is in the best interest of all parties, as well as our customers, colleagues and shareholders,” said Thomas Moriarty, CVS’ general counsel, in a statement. “We are committed to working with states, municipalities and tribes, and will continue our own important initiatives to help reduce the illegitimate use of prescription opioids.”
US states, cities and counties have filed more than 3,000 lawsuits against opioid manufacturers, distributors and pharmacies, accusing them of downplaying the addiction risk and failing to stop pills from being diverted for illegal use.
More than 500,000 overdose deaths over the past two decades – including more than 80,000 in 2021 alone – are blamed on the US opioid crisis, government data show, with an estimated 9.5 million Americans age 12 and older reported in 2020 to have misused opioids, including 9.3 million prescription pain reliever abusers and 902,000 heroin users.
Meantime, synthetic opioids, primarily fentanyl, caused nearly two-thirds of the more than 100,000 drug overdose deaths in the US in the 12-month period ending April 2021 – up 49% from the year before – the CDC’s National Center for Health Statistics found.
Opioids are drugs formulated to replicate the pain-reducing properties of opium and include prescription painkillers like morphine, oxycodone and hydrocodone and illegal drugs like heroin and illicitly made fentanyl.
People who become dependent on opioids may experience withdrawal symptoms when they stop using it, and dependence is often coupled with tolerance, meaning users need to take increasingly larger doses for the same effect.
A federal judge in August ruled CVS, Walgreens and Walmart must pay a combined $650.6 million to two Ohio counties for damages related to the opioid crisis. The lawsuit was initially filed in 2018 as part of federal multi-district litigation created that year to address the manifold claims against opioid manufacturers and distributors.
Teva Pharmaceutical Industries in July announced a $4.35 billion proposed nationwide settlement that could resolve thousands of lawsuits over the drugmaker’s alleged role in the US opioid epidemic.
Purdue Pharma – whose OxyContin painkiller has been widely blamed for kickstarting the opioid crisis – and the Sackler families in March announced a settlement with a group of states that would require the Sacklers to pay out as much as $6 billion to states, individual claimants and opioid crisis abatement, if approved by a federal bankruptcy court judge.
And Johnson & Johnson and the three largest US drug distributors – McKesson Corp, Cardinal Health Inc and AmerisourceBergen Corp – finalized a $26 billion nationwide opioid settlement in February.
according to people familiar with the situation, as healthcare heavyweights scramble to snap up primary-care providers.
The talks are serious and a deal to purchase Cano could be struck in the next several weeks, assuming the negotiations don’t fall apart, some of the people said. Cano shares, which had been down nearly 7%, turned positive and closed up 32% after The Wall Street Journal reported on the talks with Humana and other unnamed parties, giving the company a market value of roughly $4 billion.
Bloomberg subsequently reported CVS’s interest.
It couldn’t be learned which other potential buyers might be in the mix, but Cano could be Humana’s to lose as the health insurer has a right of first refusal on any sale, part of an agreement that was originally struck in 2019.
Miami-based Cano operates primary-care centers in California, Florida, Nevada, New Mexico, Texas, Illinois, New York, New Jersey and Puerto Rico, according to documentation from the company. It mainly serves Medicare Advantage members, a private-sector alternative to Medicare for seniors.
Ties between the companies run deep: Cano was Humana’s biggest independent primary-care provider in Florida, serving over 68,000 of its Medicare Advantage members at the end of last year, according to a securities filing. Cano also operated 11 medical centers in Texas and Nevada for which Humana is the exclusive health plan for Medicare Advantage, the filing added.
Humana has already established a footprint in primary care, which it continues to expand. Earlier this year, its CenterWell Senior Primary Care business joined with private-equity firm Welsh, Carson, Anderson & Stowe to open about 100 new senior-focused primary-care clinics between 2023 and 2025, building on an earlier, similar partnership.
Newsletter Sign-up
Alert
Deals
Major news in the world of deals and deal-makers.
At its investor day last week, Humana’s chief executive,
Bruce Broussard,
said that the company sees a total addressable market of over $700 billion in “value-based” primary care for seniors. He noted that Humana has accelerated its investment in the sector over the past five years, becoming the nation’s largest senior-focused primary-care provider.
There has been a frenzy of deal making involving large companies scooping up primary-care assets as a means of getting closer to patients and providing them more personal service.
Amazon.com Inc.
agreed to purchase the parent of primary-care clinic operator One Medical for about $3.9 billion in July, while CVS Health Corp. agreed to buy
Signify Health Inc.
for $8 billion earlier this month.
Cano went public in 2020 through a special-purpose acquisition vehicle backed by real-estate investor
Barry Sternlicht,
who sits on its board. The deal valued the company at $4.4 billion.
Cano has been the target of two shareholder activists this year, both of which independently pushed for its sale.
Dan Loeb’s
Third Point LLC currently has a roughly 5% stake in the healthcare company. In March, he pointed to the market’s unfavorable view of companies that went public through SPACs as a reason to explore strategic alternatives.
Then in late August, Owl Creek Asset Management LP sent a letter to Cano’s board stating that it had amassed a roughly 4% stake and urged the company to hire investment bankers to explore a sale to a strategic buyer.
Cano has been backed by health-care-focused private-equity firm InTandem Capital Partners since 2016. The firm mainly makes investments in small-to-midsize companies.
—Cara Lombardo contributed to this article.
Write to Laura Cooper at laura.cooper@wsj.com and Dana Cimilluca at dana.cimilluca@wsj.com
A Danbury-based addiction-treatment nonprofit plans to move its local outpatient clinic to the former CVS site at Whalley Avenue and Orchard Street, after purchasing that recently shuttered ex-pharmacy property for $2.5 million.
On Monday, Midwestern Connecticut Council of Alcoholism Inc. (MCCA) bought the 1.15-acre commercial property at 215 Whalley Ave. from the Brandfon Family Limited Partnership for $2.5 million, according to a recent filing on the city’s online land records database.
That property — previously home to a CVS pharmacy, which closed its doors earlier this year — was most recently appraised by the city as worth $2,427,600.
Founded in 1972, MCCA bills itself on its website as “the primary provider of substance abuse prevention, evaluation and treatment services in the greater Danbury area.” It currently operates seven outpatient clinics in Danbury, Milford, Waterbury, Bridgeport, and in the Whalley-Edgewood-Beaver Hills neighborhood at 419 Whalley Ave.
In a brief email exchange with the Independent on Wednesday, MCCA Chief Financial Officer Glenn Connan said that MCCA purchased the former CVS site with the intention of moving its current Whalley Avenue clinic to that location.
“We currently operate our New Haven Outpatient Clinic just up the road at 419 Whalley Avenue and are just looking to relocate to better serve the community,” Connan wrote.
He did not respond to a follow up request for comment on what specific types of medical services will be provided at this location, how many patients MCCA expects to treat there, and what if any types of changes to the prominent Whalley Avenue corner property the healthcare nonprofit intends to make.
MCCA’s website states that it offers at all seven of its outpatient clinics medication-assisted treatment – such as Suboxone, Naltrexone, and Subutex — in combination with “counseling and behavioral therapies” to treat patients struggling with opioid addictions.
Its website also says that the current outpatient clinic at 419 Whalley Ave. offers a range of “addiction services,” including outpatient treatment, intensive outpatient, and programs for pre-trial intervention, anger management, and relapse prevention.
“Our New Haven Outpatient Clinic offers a full-range of outpatient treatment options for those dealing with addiction. From individual to group to intensive outpatient (IOP), our supportive therapies help clients to recognize their triggers and destructive behavior and begin to create the positive changes leading to a healthier lifestyle and improved sense of well-being,” the MCCA site reads in part.
“Intensive Outpatient (IOP) is ideal for individuals unable to enter a residential program due to work and family obligations. One of our most popular groups for individuals struggling with drug or alcohol addiction, IOP meets three times a week for three-hour sessions.”
The New Haven Independent is a not-for-profit public-interest daily news site founded in 2005.
It’s a holiday that recognizes the contributions and achievements of American workers and is celebrated on the first Monday of September.
Here’s everything you need to know about store hours on Monday for Labor Day 2022 (9/5/22).
What stores are open on the Labor Day 2022? When do stores close?
Here is a list of many popular retailers that are confirmed to be open on the Labor Day 2022, along with their store hours, according to their websites, Reader’s Digest and USA Today.
Note: Shoppers should ultimately check with their local store in the event hours vary by location.
24 Hour Fitness (24 hours; varies by gym)
7-Eleven (24 hours; varies by store)
Aldi (9 a.m. – 6 p.m.; varies by store)
Apple (11 a.m. – 8 p.m.; varies by store)
Barnes and Noble (10 a.m. – 9 p.m.)
Bass Pro Shops (9 a.m. – 9 p.m.; varies by store)
Bath & Body Works (10 a.m. – 9 p.m.; varies by store)
Bed Bath & Beyond (10 a.m. – 8 p.m.; varies by store)
Best Buy (10 a.m. – 8 p.m.; varies by store)
Big Lots (9 a.m. – 9 p.m.)
BJ’s Wholesale Club (9 a.m. – 9 p.m.; varies by store)
Boscov’s (9 a.m. – 9 p.m.)
Burlington (9:30 a.m. – 11 p.m.)
Chick-fil-A (10:30 a.m. – 6 p.m.; varies by store)
Costco (CLOSED)
CVS (varies by store)
Dick’s Sporting Goods (9 a.m. – 9 p.m.)
Dollar Tree (9 a.m. – 9 p.m.; varies by store)
Dunkin’ (varies by store)
GameStop (12 p.m. – 6 p.m.; varies by store)
Goodwill (9 a.m. – 6 p.m.)
Hobby Lobby (9 a.m – 5:30 p.m.)
Home Depot (6 a.m. – 10 p.m.)
Ikea (10 a.m. – 9 p.m.)
JCPenney (11 a.m. – 8 p.m.; varies by store)
Kohl’s (10 a.m. – 9 p.m.)
Lowe’s (6 a.m. – 10 p.m.)
Macy’s (10 a.m. – 9 p.m.; varies by store)
Marshalls (9:30 a.m. – 9:30 p.m.)
McDonald’s (varies by store)
Nordstrom (10 a.m. – 9 p.m.; varies by store)
Nordstrom Rack (10 a.m. – 9 p.m.; varies by store)
Old Navy (10 a.m. – 9 p.m.; varies by store)
Petco (9 a.m. – 8 p.m.; varies by store)
PetSmart (9 a.m. – 6 p.m.; varies by store)
Rite Aid (8 a.m. – 10 p.m.; varies by store)
REI (10 a.m. – 8 p.m.)
Sam’s Club (Plus Members: 8 a.m. – 6 p.m.; Club Members: 10 a.m. – 6 p.m.)
There are plenty of online sales for Labor Day. Here are a few:
Samsung’s Labor Day discounts on tech and home appliances
Walmart’s Labor Day sale with rollback prices on items storewide, including home goods and tech
Coach’s Labor Day sale with 25% off select handbags, shoes, apparel and accessories
Amazon’s sale on fashion, tech, home goods and kitchen essentials
Wayfair’s Labor Day sale with up to 70% off furniture, mattresses and home goods
Kohl’s clearance sale with select items storewide up to 70% off
RELATED STORIES ABOUT RETAIL AND SHOPPING:
Pizzeria known for 1 of N.J.’s greatest pies announces plans to close
Popular N.J. hotel and indoor water park to reopen under new ownership
N.J.-based clothing company Faherty opens 3rd Garden State store
Our journalism needs your support. Please subscribe today to NJ.com.
Christopher Burch can be reached at cburch@njadvancemedia.com. Follow him on Twitter: @ChrisBurch856. Find NJ.com on Facebook. Have a tip? Tell us. nj.com/tip
CVS Health Corp. has reportedly taken the lead in the battle among heavyweights for the home-healthcare company Signify Health Inc.
CVS is said to be in advanced talks with a bid of around $8 billion, according to Bloomberg.
Signify is a provider of technology and services for home health.
The companies could announce a deal next week with a value of more than $30 a share.
UNITEDHEALTH, AMAZON, CVS HEALTH, OPTION CARE BIDDING ON SIGNIFY HEALTH
CVS was reportedly offering to purchase Signify as the retail company pursues efforts to expand in-home health services. (Alex Tai/SOPA Images/LightRocket via Getty Images / Getty Images)
Amazon.com and UnitedHealth Group have also been interested in making a deal.
There is still no guarantee that CVS will reach a deal for Signify, which has been exploring strategic alternatives since earlier this summer.
Representatives for Signify and CVS declined to comment.
UnitedHealth Group, Amazon, CVS Health and Option Care Health have been interested in bidding for Signify Health. (Igor Golovniov/SOPA Images/LightRocket via Getty Images / Getty Images)
Amazon announced in July that it will acquire U.S. primary health care provider One Medical for $18 per share, in an all-cash deal valued at about $3.9 billion.
CVS PLANS TO MAKE A MOVE INTO PRIMARY CARE BY END OF 2022
That deal is under investigation as the Federal Trade Commission has asked for more information on the acquisition.
Ticker
Security
Last
Change
Change %
CVS
CVS HEALTH CORP.
99.47
-0.43
-0.43%
SGFY
SIGNIFY HEALTH INC
28.77
+0.38
+1.34%
UNH
UNITEDHEALTH GROUP INC.
516.35
-7.65
-1.46%
AMZN
AMAZON.COM INC.
127.51
-0.31
-0.24%
The Wall Street Journal reported earlier that CVS was in advanced talks to buy Signify.
A CVS pharmacy is seen in Bloomsburg, Pennsylvania. ( Paul Weaver/SOPA Images/LightRocket via Getty Images / Getty Images)
CLICK HERE TO READ MORE ON FOX BUSINESS
Signify rose 1.3% to close at $28.77 in New York trading Friday, giving it a market value of about $6.7 billion.
FOX Business’ Landon Mion contributed to this report.